# A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

> **NCT02260635** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 54 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Evacetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02260635
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-12
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Study termination due to insufficient efficacy.
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260635, "A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02260635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*